CareDx, Inc (NASDAQ:CDNA – Free Report) – HC Wainwright raised their Q3 2024 EPS estimates for shares of CareDx in a note issued to investors on Tuesday, October 22nd. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($0.23) for the quarter, up from their previous forecast of ($0.25). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for CareDx’s current full-year earnings is ($0.84) per share. HC Wainwright also issued estimates for CareDx’s FY2024 earnings at ($0.81) EPS, Q1 2025 earnings at ($0.19) EPS, Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.10) EPS and FY2025 earnings at ($0.60) EPS.
A number of other brokerages also recently issued reports on CDNA. StockNews.com upgraded shares of CareDx from a “hold” rating to a “buy” rating in a research report on Thursday, October 17th. Wells Fargo & Company began coverage on shares of CareDx in a research note on Tuesday, August 27th. They issued an “underweight” rating and a $28.00 price objective for the company. The Goldman Sachs Group lifted their price objective on shares of CareDx from $26.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. Craig Hallum lifted their price objective on shares of CareDx from $22.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Finally, BTIG Research upgraded shares of CareDx from a “neutral” rating to a “buy” rating and set a $40.00 price objective for the company in a research note on Monday, August 19th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $30.60.
CareDx Stock Performance
Shares of NASDAQ CDNA opened at $22.85 on Thursday. The company has a market capitalization of $1.19 billion, a P/E ratio of -6.68 and a beta of 1.77. CareDx has a 52-week low of $4.80 and a 52-week high of $34.84. The company’s 50 day moving average price is $29.25 and its 200-day moving average price is $20.01.
CareDx (NASDAQ:CDNA – Get Free Report) last issued its quarterly earnings results on Wednesday, July 31st. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.37. The firm had revenue of $92.27 million for the quarter, compared to the consensus estimate of $67.20 million. CareDx had a negative net margin of 53.73% and a negative return on equity of 53.65%.
Institutional Trading of CareDx
Several institutional investors have recently made changes to their positions in CDNA. GAMMA Investing LLC grew its stake in shares of CareDx by 1,021.8% in the 2nd quarter. GAMMA Investing LLC now owns 2,210 shares of the company’s stock worth $34,000 after acquiring an additional 2,013 shares in the last quarter. Plato Investment Management Ltd bought a new stake in shares of CareDx in the 2nd quarter worth $62,000. nVerses Capital LLC grew its stake in shares of CareDx by 175.0% in the 3rd quarter. nVerses Capital LLC now owns 3,300 shares of the company’s stock worth $103,000 after acquiring an additional 2,100 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in shares of CareDx in the 2nd quarter worth $142,000. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of CareDx by 10,267.2% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 18,661 shares of the company’s stock worth $198,000 after acquiring an additional 18,481 shares in the last quarter.
Insider Buying and Selling at CareDx
In other CareDx news, insider Alexander L. Johnson sold 21,557 shares of the business’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $32.58, for a total transaction of $702,327.06. Following the completion of the sale, the insider now owns 284,983 shares in the company, valued at approximately $9,284,746.14. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other CareDx news, insider Alexander L. Johnson sold 21,557 shares of the business’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $32.58, for a total transaction of $702,327.06. Following the completion of the sale, the insider now owns 284,983 shares in the company, valued at approximately $9,284,746.14. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Alexander L. Johnson sold 34,231 shares of the business’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $33.55, for a total transaction of $1,148,450.05. Following the sale, the insider now owns 284,983 shares of the company’s stock, valued at $9,561,179.65. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 91,340 shares of company stock worth $3,025,415. 4.20% of the stock is owned by corporate insiders.
About CareDx
CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
Featured Articles
- Five stocks we like better than CareDx
- Investing in Travel Stocks Benefits
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Why is the Ex-Dividend Date Significant to Investors?
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- 3 Stocks to Consider Buying in October
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.